These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 15964061

  • 1. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
    [Abstract] [Full Text] [Related]

  • 2. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [Abstract] [Full Text] [Related]

  • 3. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [Abstract] [Full Text] [Related]

  • 4. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.
    Pawlak K, Zolbach K, Borawski J, Mysliwiec M, Kovalchuk O, Chyczewski L, Pawlak D.
    Thromb Res; 2008; 123(1):166-70. PubMed ID: 18452978
    [Abstract] [Full Text] [Related]

  • 5. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
    [Abstract] [Full Text] [Related]

  • 6. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
    Pawlak K, Pawlak D, Myśliwiec M.
    Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
    [Abstract] [Full Text] [Related]

  • 7. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.
    Pawlak K, Pawlak D, Mysliwiec M.
    Clin Biochem; 2005 Aug; 38(8):700-5. PubMed ID: 15963971
    [Abstract] [Full Text] [Related]

  • 8. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
    Skrha J, Hodinár A, Kvasnicka J, Hilgertová J.
    Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
    [Abstract] [Full Text] [Related]

  • 9. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D.
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [Abstract] [Full Text] [Related]

  • 10. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease.
    Pawlak K, Pawlak D, Mysliwiec M.
    Clin Biochem; 2007 Jan; 40(1-2):81-5. PubMed ID: 17046733
    [Abstract] [Full Text] [Related]

  • 11. Global fibrinolytic capacity in children on dialysis.
    Agras PI, Baskin E, Cengiz N, Kirazli S, Saatci U, Ozbek N.
    Thromb Res; 2005 Jan; 115(3):185-9. PubMed ID: 15617740
    [Abstract] [Full Text] [Related]

  • 12. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Res; 2008 Jan; 122(3):328-35. PubMed ID: 18048089
    [Abstract] [Full Text] [Related]

  • 13. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 14. Impairment of glutathione biosynthetic pathway in uraemia and dialysis.
    Alhamdani MS.
    Nephrol Dial Transplant; 2005 Jan; 20(1):124-8. PubMed ID: 15632350
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
    Ho CH, Yuan CC, Liu SM.
    Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
    [Abstract] [Full Text] [Related]

  • 16. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease.
    Oda H, Ohno M, Ohashi H.
    Adv Perit Dial; 2000 Dec; 16():152-5. PubMed ID: 11045282
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J.
    Thromb Res; 2009 Dec; 123(3):537-42. PubMed ID: 18691743
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E, Dziedziczko A, Rość D.
    Med Sci Monit; 2000 Dec; 6(1):103-7. PubMed ID: 11208294
    [Abstract] [Full Text] [Related]

  • 19. Enhanced fibrinolytic activity during the course of hemodialysis.
    Nakamura Y, Tomura S, Tachibana K, Chida Y, Marumo F.
    Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
    [Abstract] [Full Text] [Related]

  • 20. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
    Pawlak K, Pawlak D, Mysliwiec M.
    Cytokine; 2005 Jul 07; 31(1):18-24. PubMed ID: 15896974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.